<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3116">
  <stage>Registered</stage>
  <submitdate>18/03/2011</submitdate>
  <approvaldate>18/03/2011</approvaldate>
  <nctid>NCT01320345</nctid>
  <trial_identification>
    <studytitle>A Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Fenofibrate Versus Placebo on Macular Thickness and Volume</studytitle>
    <scientifictitle>The Fenofibrate And Microvascular Event Eye (FAME 1 EYE) Trial: A Randomised Trial in Adults With Type 1 Diabetes Mellitus Evaluating the Effects of Daily Oral Fenofibrate Compared With Placebo on Macular Thickness and Volume</scientifictitle>
    <utrn />
    <trialacronym>FAME 1 EYE</trialacronym>
    <secondaryid>ACTRN12611000249954</secondaryid>
    <secondaryid>FAME0001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 1 Diabetes Mellitus</healthcondition>
    <healthcondition>Retinopathy</healthcondition>
    <healthcondition>Diabetic Nephropathy</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Fenofibrate
Treatment: drugs - Inert lactose placebo

Experimental: Fenofibrate - 

Placebo Comparator: Placebo - 


Treatment: drugs: Fenofibrate
Oral Fenofibrate 145mg given once daily for 12 months.

Treatment: drugs: Inert lactose placebo
Oral matching inert lactose placebo given once daily for 12 months.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Central zone macular thickness measured using optical coherence tomography</outcome>
      <timepoint>At 12 months after randomisation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Total macular volume measured using optical coherence tomography.</outcome>
      <timepoint>At 12 months after randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Albuminuria measured as urinary albumin:creatinine ratio.</outcome>
      <timepoint>Assessed at 12 months after randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Visual acuity using Snellen Chart</outcome>
      <timepoint>At 12 months after randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Corneal confocal microscopic measurement of neural damage (only assessed in a representative subset of the participants at sites with the specialised confocal microscope).</outcome>
      <timepoint>At 12 months after randomisation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Estimated glomerular filtration rate using MDRD formula</outcome>
      <timepoint>At 12 months after randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peripheral neuropathy status assessed by temperature sensation and monofilament sensation.</outcome>
      <timepoint>At 12 months after randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Vascular function using non-invasive pulse wave techniques and plethysmography.</outcome>
      <timepoint>At 12 months after randomisation.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood lipids and biomarkers in plasma</outcome>
      <timepoint>At 6 weeks, 6 months and 12 months after randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects with type 1 diabetes mellitus

          -  Over 18 years of age

          -  Established macular thickening on optical coherence tomography (OCT) greater than or
             equal to 300 micrometres in at least one macular zone

          -  No definite indication for receiving, and no contraindication to receiving fenofibrate
             in addition to their existing therapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects with type 1 diabetes mellitus and the contraindications of definite need for
             intra-ocular treatment or photocoagulation therapy within next 3 months

          -  Allergy to any fibrate drugs

          -  History of pancreatitis or pulmonary embolism or DVT

          -  Use of any other investigational agents in last 8 weeks

          -  Unstable condition including recent MI, heart failure, prior organ transplant, severe
             renal or liver dysfunction, history of myositis or untreated hypothyroidism</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/09/2014</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>NHMRC Clinical Trials Centre - Camperdown</hospital>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Westmead Children's Hospital - Westmead</hospital>
    <hospital>Royal Melbourne Hospital - Melbourne</hospital>
    <hospital>St Vincents Hospital - Melbourne</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>3050 - Melbourne</postcode>
    <postcode>3065 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Abbott</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Melbourne</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>St Vincent's Hospital Melbourne</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Melbourne Health</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Royal Prince Alfred Hospital, Sydney, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the potential benefits of Fenofibrate in 300 adults
      with Type 1 diabetes mellitus who are at high risk of eye damage.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01320345</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Anthony Keech, Professor</name>
      <address>University of Sydney, NHMRC Clinical Trials Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Anthony Keech, Professor</name>
      <address />
      <phone>+61 2 95625003</phone>
      <fax />
      <email>tony@ctc.usyd.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>